MedTrace Logo

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

NCT03809988 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2023-09-07

No results posted yet for this study

Summary

Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)

Conditions

Interventions

DRUG

Palbociclib

Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks

DRUG

Endocrine therapy

Endocrine therapy alone (letrozole or fulvestrant)

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • MedSIR

    lead OTHER

Principal Investigators

  • José Perez · MedSIR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-05
Primary Completion
2022-11-30
Completion
2022-11-30

Countries

  • France
  • Germany
  • Italy
  • Slovenia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03809988 on ClinicalTrials.gov